Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities

27 Apr 2017

• By Emily Hayes

Opdivo first-quarter sales were still strong at $1.1bn, largely driven by lung cancer use and helping to drive overall performance, but potential approval of Merck's competing Keytruda with chemotherapy in first-line lung cancer is right around the corner.

BMY Chief Scientific Officer Thomas Lynch — Bristol's Chief Scientific Officer Thomas Lynch • Source: Bristol-Myers Squibb

Bristol-Myers Squibb Co.'s new Chief Scientific Officer Thomas Lynch championed the company's lung cancer strategy and laid out immuno-oncology R&D priorities going forward, including a heavy emphasis on translational medicine, during Bristol's first quarter earnings call April 27.

The company reported sales of $4.9bn in the first quarter, which was above expectations and driven by better-than-expected performance of its PD-1 inhibitor Opdivo (nivolumab), its novel oral anticoagulant Eliquis (apixaban) and the CTLA-4 inhibitor Yervoy (ipilimumab), among other drugs (see table)

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

05 May 2025

• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label

28 Apr 2025

• By Joseph Haas

With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

28 Apr 2025

• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

25 Apr 2025

• By Alaric DeArment

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.